Singapore Proposes New Regulatory Framework for Complementary Health Products: What Businesses Need to Know

What's Changed?

On 1 July 2026, Singapore's Health Sciences Authority (HSA) launched a stakeholder consultation on a proposed regulatory framework for Complementary Health Products (CHP) under the Health Products Act.

The consultation is open from 1 July to 29 July 2026, inviting industry stakeholders and other interested parties to provide feedback on the proposed regulatory controls.

The proposed framework covers a broad range of products, including health supplements, traditional medicines (excluding traditional Chinese medicines), homoeopathic medicines, medicated oils, balms and plasters, and topical antiseptics.

HSA is proposing a more structured regulatory approach that would introduce requirements relating to:

• Product notification

• Product safety and quality

• Product labelling

• Record keeping and safety reporting

• Advertisement controls

• Implementation timelines

Under the proposed framework, HSA also intends to require the person instrumental in placing a CHP on the local market to notify HSA of key product information. This would support post-market surveillance and enable timely regulatory action when safety issues are identified.

Why This Change Matters

The proposed framework could represent a significant shift in how complementary health products are regulated in Singapore.

At present, certain complementary health products, including health supplements, can be voluntarily notified to HSA, with companies self-assessing compliance against applicable safety, quality, and labelling standards.

The proposed framework would move toward a more formal regulatory structure, increasing expectations around product information, safety monitoring, record keeping, labelling, and advertising.

For businesses operating in this sector, the proposed changes could therefore have implications for regulatory strategy, compliance systems, product documentation, and post-market responsibilities.

However, it is important to note that the framework is still under consultation. The final requirements and implementation timeline may evolve following stakeholder feedback.

Who Needs to Pay Attention?

The proposed regulatory changes are particularly relevant to:

✔ Health supplement companies

✔ Traditional medicine manufacturers and suppliers

✔ Homoeopathic medicine businesses

✔ Companies marketing medicated oils, balms, and plasters

✔ Manufacturers and suppliers of topical antiseptics

✔ Importers and distributors

✔ Regulatory affairs and compliance professionals

✔ Businesses planning to enter Singapore's complementary health products market

Companies already operating in Singapore, as well as businesses considering market entry, should monitor the consultation process and any subsequent regulatory developments.

What Companies Should Do Next

1. Review Your Product Portfolio

Companies should identify products that could fall within the proposed definition and scope of Complementary Health Products.

Understanding how individual products may be classified will be an important first step in assessing potential regulatory impact.

2. Assess Current Compliance Systems

Businesses should review their existing processes for:

• Product information management

• Labelling

• Safety monitoring

• Record keeping

• Advertising and promotional claims

  
  

This can help identify potential gaps if the proposed framework is implemented.

3. Monitor the Consultation Outcome

Because the framework is still being developed, companies should closely follow HSA announcements and any subsequent guidance or legislation.

The final requirements may differ from the proposals currently under consultation.

4. Prepare for Greater Post-Market Accountability

The proposed product notification and safety reporting requirements indicate a potential shift toward stronger post-market oversight.

Businesses should therefore consider whether their existing systems can support effective monitoring and timely reporting of safety concerns.

ARQon Insight

Singapore's proposed framework highlights an important evolution in healthcare regulation: regulatory oversight increasingly extends beyond the point of market entry.

For businesses operating in the complementary health products sector, future compliance may depend not only on meeting product safety and quality expectations but also on maintaining robust systems for product information, traceability, record-keeping, safety reporting, and responsible advertising.

The consultation period also presents an opportunity for industry stakeholders to engage with the regulatory process.

Companies that actively monitor proposed changes and assess their potential impact early will be better positioned to adapt when new requirements are finalised.

Global Regulatory Trend

Singapore's proposed approach reflects a broader international movement toward strengthening oversight of products positioned between conventional consumer goods and regulated medicines.

As consumers increasingly turn to health supplements and complementary health products, regulators worldwide are placing greater emphasis on:

• Product safety and quality

• Accurate consumer information

• Responsible advertising

• Traceability

• Post-market surveillance

For international companies, this means that regulatory strategies for complementary health products can no longer rely solely on traditional market-entry assessments.

Businesses should increasingly consider the full product lifecycle, from classification and market entry through to ongoing safety monitoring and compliance.

Key Takeaway

Singapore's 1 July 2026 stakeholder consultation marks an important potential development in the regulation of Complementary Health Products.

While the proposed framework has not yet been finalised, its scope signals a possible move toward more structured oversight of product notification, safety and quality, labelling, record keeping, safety reporting, and advertising.

For businesses operating in or planning to enter Singapore's complementary health products market, this is the time to monitor the consultation process, assess potential regulatory impact, and prepare for possible changes.

Early regulatory intelligence can give companies valuable time to adapt their compliance strategies before new requirements take effect.

How ARQon Can Support

ARQon supports healthcare and life sciences companies with:

• Regulatory intelligence and monitoring

• Singapore market entry strategy

• Product classification and regulatory assessment

• Compliance and regulatory gap analysis

• Regulatory change impact assessments

• Cross-border market access planning

• Global regulatory strategy

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.